Studies indicate that Anika Therapeutics’ HYALOFAST® biodegradable HA-based scaffold + autologous adult mesenchymal stem cells (MSCs) is a viable, effective option to treat knee cartilage lesions, regardless of patient age.
Specifically, the data revealed equally effective outcomes in patients both under and over the age of 45. The latter are difficult to treat with traditional methods, such as microfracture.
The 4-year study evaluated 40 patients split equally into two groups, above or below age 45, all treated with HYALOFAST + MSCs. At final follow-up, all functional outcome scores improved significantly in both groups. Researchers concluded that outcomes were not impacted by age or other surgical procedures, but by the size and quantity of lesions.
HYALOFAST is available in >15 countries and has been used in >11,000 patients, to date. The product’s FastTRACK Phase III trial is enrolling ~200 patients at up to 30 U.S. and EU sites, studying its use in articular knee cartilage defect lesions.
Studies indicate that Anika Therapeutics' HYALOFAST® biodegradable HA-based scaffold + autologous adult mesenchymal stem cells (MSCs) is a viable, effective option to treat knee cartilage lesions, regardless of patient age.
Specifically, the data revealed equally effective outcomes in patients both under and over the age of 45. The latter are...
Studies indicate that Anika Therapeutics’ HYALOFAST® biodegradable HA-based scaffold + autologous adult mesenchymal stem cells (MSCs) is a viable, effective option to treat knee cartilage lesions, regardless of patient age.
Specifically, the data revealed equally effective outcomes in patients both under and over the age of 45. The latter are difficult to treat with traditional methods, such as microfracture.
The 4-year study evaluated 40 patients split equally into two groups, above or below age 45, all treated with HYALOFAST + MSCs. At final follow-up, all functional outcome scores improved significantly in both groups. Researchers concluded that outcomes were not impacted by age or other surgical procedures, but by the size and quantity of lesions.
HYALOFAST is available in >15 countries and has been used in >11,000 patients, to date. The product’s FastTRACK Phase III trial is enrolling ~200 patients at up to 30 U.S. and EU sites, studying its use in articular knee cartilage defect lesions.
Copy to clipboard 
